Scholar Rock HoldingNASDAQ: SRRK

Scholar Rock Holding Corporation (NASDAQ:SRRK ) Q3 2024 Earnings Conference Call November 12, 2024 8:15 AM ET Company Participants Jay Backstrom - President & CEO Ted Myles - COO & CFO Conference Call Participants Jenna Lee - Jefferies Etzer Darout - BMO Capital Markets Gary Nachman - Raymond James Alex Nugent - Truist Securities Limited Operator Good morning and welcome to Scholar Rock's Third Quarter 2024 Financial Results and Business Update Call. All participants will be in listen-only mode.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will host a conference call to discuss its third quarter 2024 financial results and provide a business update on Tuesday, November 12, 2024, at 8:15am ET. To access the live conf.

Scholar Rock Holding Corporation (SRRK) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, SRRK's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.

Successful clinical-trial results recently made Scholar Rock one of the stock market's top performers.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock Holding Corporation (Nasdaq: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced the pricing of an upsized underwritten public offering of 10,265,488 shares of its common stock at a public offering price of $28.25 per share and, in lieu of common stock to.

Scholar Rock stock skyrockets as the late-stage study of the investigational therapy, apitegromab, to treat spinal muscular atrophy meets the primary goal.

Shares of Scholar Rock Holding Corp. (SRRK, Financial) soared by 335% as their candidate drug for spinal muscular atrophy (SMA), apitegromab, achieved the primary endpoint in a Phase 3 trial. The positive results indicate that the apitegromab monoclonal antibody significantly improves motor function in patients.

Apitegromab met the primary endpoint in its phase 3 SAPPHIRE study for spinal muscular atrophy, setting up BLA & MAA filings in Q1 2025. Apitegromab is the first treatment targeting muscle fiber atrophy in SMA, potentially changing the standard of care and offering a competitive edge. Scholar Rock also has apitegromab being explored in a phase 2 study for obesity, with clinical data expected in Q2 2025, presenting another catalyst.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will participate in the following upcoming investor conferences in September: Morgan Stanley 22nd Annual Global Healthcare Conference: Scholar Rock is scheduled to participate in.